Alzamend Neuro, Inc. (NASDAQ:ALZN) Short Interest Update

Alzamend Neuro, Inc. (NASDAQ:ALZN) saw a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 120,900 shares, a decline of 47.0% from the February 28th total of 228,200 shares. Approximately 1.9% of the shares of the company are sold short. Based on an average trading volume of 376,700 shares, the short-interest ratio is presently 0.3 days.

Institutional Trading of Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Geode Capital Management LLC acquired a new stake in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 33,540 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned about 0.62% of Alzamend Neuro as of its most recent SEC filing. Institutional investors own 49.61% of the company’s stock.

Alzamend Neuro Stock Down 3.6 %

ALZN stock opened at $1.06 on Friday. Alzamend Neuro has a twelve month low of $0.64 and a twelve month high of $15.06. The business’s 50-day moving average price is $0.99 and its 200-day moving average price is $1.28.

Alzamend Neuro (NASDAQ:ALZN) last released its earnings results on Monday, March 10th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.10. On average, analysts expect that Alzamend Neuro will post -1.68 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets lowered their price objective on shares of Alzamend Neuro from $32.00 to $20.00 and set a “buy” rating on the stock in a research note on Monday, March 17th.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.